RANI

Rani Therapeutics Holdings, Inc.

0.87 USD

Last updated Sep 4, 20:44 UTC

Yesterday HIGH

$0.87

Yesterday LOW

$0.84

52w HIGH

$3.87

52w LOW

$0.44

EPS

-0.04

PE

-21.72

Next Earnings

Nov 5, 2026

Overview News Government Trades Fundamentals

Rani Therapeutics Holdings, Inc. stock is up 11.41% since 30 days ago. The next earnings date is Nov 5, 2026. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 20% of the previous 5 September’s closed higher than August. 100% of analysts rate it a buy.

Benzinga Newsdesk

Thu Aug 13, 2026

Rani Therapeutics Hldgs Q2 EPS $(0.04) Beats $(0.05) Estimate, Sales $1.708M Beat $925.000K Estimate

Rani Therapeutics Hldgs (NASDAQ:RANI) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.05) by 20 percent. This is a 77.78 percent increase over losses of $(0.18) per share
Benzinga Insights

Wed Jul 22, 2026

12 Health Care Stocks Moving In Wednesday's Intraday Session

Gainers Advanced Biomed (NASDAQ:ADVB) shares moved upwards by 108.6% to $14.77 during Wednesday's regular session. The company's market cap stands at $11.5 million. Lakewood-Amedex (NASDAQ:LABT) shares moved
Benzinga Newsdesk

Wed Jul 15, 2026

Rani Therapeutics Reports Initial Phase 1 Data Showing Oral RT‑114 Delivered Systemic Exposure Exceeding Matched Subcutaneous Administration, With Safety And Tolerability Consistent With GLP‑1/GLP‑2 Agonist Class

RT-114 achieved systemic exposure greater than 150% relative to a matched 12mg subcutaneous dose of PG-102 No adverse events attributed to RaniPill Capsule; treatment-related adverse events were mild and consistent with
Benzinga Newsdesk

Thu Jul 9, 2026

Rani Therapeutics Partners With PegBio To Mull Delivery Of Multiple Novel Candidates From PegBio's Obesity And Metabolic Disease Pipeline Through RaniPill Platform

Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced a research
Benzinga Newsdesk

Mon Jun 29, 2026

Rani Therapeutics Appoints Nicholas Maestas As CFO; Succeeds Svai Sanford
Benzinga Newsdesk

Tue May 26, 2026

Rani Therapeutics shares are trading lower after the company priced a $20 million registered direct offering.
Benzinga Newsdesk

Tue May 26, 2026

Rani Therapeutics Prices ~$20M Offering Of 12.48M Common Shares At $1.07/Share

Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it has entered into a
Benzinga Newsdesk

Fri May 15, 2026

Rani Therapeutics CFO Svai Sanford To Depart From Company After Successor Found
Benzinga Newsdesk

Fri May 15, 2026

Rani Therapeutics Hldgs Q1 EPS $(0.04), Inline, Sales $1.708M Beat $500.000K Estimate

Rani Therapeutics Hldgs (NASDAQ:RANI) reported quarterly losses of $(0.04) per share which met the analyst consensus estimate. This is a 81.82 percent increase over losses of $(0.22) per share from the same period last
Benzinga Newsdesk

Wed Apr 1, 2026

Canaccord Genuity Maintains Buy on Rani Therapeutics Hldgs, Lowers Price Target to $5

Canaccord Genuity analyst Edward Nash maintains Rani Therapeutics Hldgs (NASDAQ:RANI) with a Buy and lowers the price target from $9 to $5.